Jan 30, 2024 7:00am EST Can-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication
Jan 29, 2024 7:00am EST Can-Fite: Top Scientific Journal Published Positive Data from the COMFORT-1 Phase III Psoriasis Study
Dec 20, 2023 7:00am EST The Anti-Obesity Effect of Can-Fite’s Namodenoson: Molecular Mechanism of Action in Pre-clinical and Human Studies
Dec 04, 2023 7:00am EST Can-Fite’s Namodenoson for the Treatment of Pancreatic Cancer Patients: Progress in Clinical Development
Nov 21, 2023 1:53pm EST Can-Fite Announces Exercise of Warrants for Approximately $3.0 Million in Gross Proceeds
Nov 21, 2023 7:00am EST Can-Fite: Complete Response and 6.9 Years Overall Survival in a Patient with Advanced Liver Cancer Treated with Namodenoson
Nov 01, 2023 7:00am EDT Can-Fite Issues Business Update: All Clinical Programs and Business Development Activities Remain Solidly on Track
Oct 30, 2023 7:00am EDT Can Fite: Namodenoson Inhibits Pancreatic Carcinoma Published in Leading Scientific Journal; Robust anti-Cancer Effect & Molecular Mechanism of Action
